References
Caudle AS, Gonzalez-Angulo AM, Hunt KK, Pusztai L, Kuerer HM, Mittendorf EA, et al. Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol. 2011;18:932–8.
de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature. 2010;467:543–9.
Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12:236–44.
Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. 2011;11:81–92.
Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med. 2010;4(4):583–6. No abstract available.
Roukos DH, Katsios C, Liakakos T. Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn. 2010;10(5):541–5.
Roukos DH. Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics. 2010;11(8):1039–43.
Roukos DH. Translating epigenetics into an anticancer drug pipeline for solid tumors. Expert Rev Med Devices. 2011;8(4):409–13.
Roukos DH. Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics. 2011;12(5):695–8.
Roukos DH. Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices. 2011;8(2):123–6.
Roukos DH. Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol. 2011;18(1):12–5.
Roukos DH. Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices. 2010;7(6):723–6.
Katsios C, Roukos DH. Individual genomes and personalized medicine: life diversity and complexity. Personal Med. 2010;7(4):347–50.
Roukos DH, Ziogas D. From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther. 2010;10(2):123–8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Batsis, C. Strategy for Nonresponder Breast Cancer Patients to Neoadjuvant Treatment. Ann Surg Oncol 18 (Suppl 3), 286–287 (2011). https://doi.org/10.1245/s10434-011-1980-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-011-1980-0